Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Abstract

The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain. One hundred and nineteen patients with LAPC, World Health Organization performance status of zero to two were randomly assigned to either the induction CHRT group (60 Gy, 2 Gy/fraction; concomitant 5-fluorouracil infusion, 300 mg/m(2)/day, days 1-5 for 6 weeks; cisplatin, 20 mg/m(2)/day, days 1-5 during weeks 1 and 5) or the induction gemcitabine group (GEM: 1000 mg/m(2) weekly for 7 weeks). Maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks) was given in both arms until disease progression or toxicity. Overall survival was shorter in the CHRT than in GEM arm [median survival 8.6 (99% confidence interval 7.1-11.4) and 13 months (8.7-18.1), P = 0.03]. One-year survival was, respectively, 32% and 53%. These results were confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy. More overall grades 3-4 toxic effects were recorded in the CHRT arm, both during induction (36 versus 22%) and maintenance (32 versus 18%). This intensive induction schedule of CHRT was more toxic and less effective than gemcitabine alone.

Keywords

MeSH Terms

Affiliated Institutions

• Université de Reims Champagne-Ardenne FR
• CHU Ambroise Paré BE
• Université Marie et Louis Pasteur
• Institut Sainte Catherine FR
• Centre Hospitalier Universitaire de Besançon FR
• Centre Georges François Leclerc FR
• Fédération Francophone de Cancérologie Digestive FR
• Hôpital Lyon Sud FR
• Hôpital Beaujon FR
• Centre Hospitalier Universitaire de Reims FR
• Maison des Sciences sociales et des Humanités de Dijon FR

Related Publications